TTrialPathMatch Me to Trials
← Back to trials
RecruitingRelapsed CancerRefractory Multiple MyelomaMultiple Myeloma

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

Sponsor: Massachusetts General Hospital

You may qualify if…

  • ✓ Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to their future medical care.
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix A).
  • ✓ Age ≥ 18 years
  • ✓ Measurable disease of multiple myeloma as defined by at least one of the following:
  • ✓ Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval
  • ✓ ≥ 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
  • ✓ Involved serum free light chain ≥ 100 mg/L (10 mg/dL) and abnormal serum free light chain ratio
  • ✓ Previously treated relapsed and refractory multiple myeloma:

You may not qualify if…

  • ✕ Participant must not have had current corneal epithelial disease except mild changes in corneal epithelium.
  • ✕ Participant must not use contact lenses while participating in this study.
  • ✕ Participants who have had myeloma therapy or investigational drug within 2 weeks prior to start of treatment or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
  • ✕ Participants who are receiving any investigational agents.
  • ✕ Prior therapy with anti-CD38 monoclonal antibody within six months. No other multiple myeloma monoclonal antibody therapy within 30 days of start of study treatment.
  • ✕ Prior therapy with anti-BCMA therapy.
  • ✕ Plasmapheresis within seven days prior to start of study treatment.
  • ✕ Primary refractory disease.

Where it's recruiting

Source: ClinicalTrials.gov · NCT05922501 · last updated 2026-01-14

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Mye · TrialPath